Teladoc Health에 대한 매도 수량은 투자자에게 Teladoc Health의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Teladoc Health (NYSE:TDOC) 주식, 공매도 수량 보고

Teladoc Health

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

Equities

Mid Cap

News

Movers

Tech

Trading Ideas

ASTS

IREN

MGNI

OKLO

TDOC

VNET

이 10개 중형주는 지난주 최고의 성과를 거두었습니다. 그것들이 당신의 포트폴리오에 있나요? 1. 킹소프트 클라우드(NASDAQ:KC)의 주식은 34.77% 상승했다.

AST 스페이스모바일, 텔레닥 헬스 및 아이렌 등 지난주 최대 상승한 중형주 (2월 3일-2월 7일)

Earnings

Guidance

Health Care

After-Hours Center

텔레닥 헬스(NYSE:TDOC)의 주가는 회사가 분석가 기대치를 뛰어넘는 3분기 재무 결과를 보고한 후 수요일 시간외 거래에서 11% 이상 급등했다.

텔레닥 헬스의 주식은 예상을 넘는 3분기 실적에 시간외 거래에서 11% 이상 급등

Markets

$BTC

$ETH

ARKF

ARKK

ARKW

COIN

PINS

수요일에 캐시 우드가 주도하는 아크 인베스트(Ark Invest)는 어드밴스드 마이크로 디바이시스(NASDAQ:AMD), 핀터레스트(NYSE:PINS), 코인베이스 글로벌(NASDAQ:

아크 인베스트가 AMD 주식을 $47.5백만 그리고 핀터레스트 주식을 $12.7백만 매수

Teladoc Health Inc

<p>In the latest quarter, 8 analysts provided ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Teladoc Health, revealing an average target of $12.88, a high estimate of $16.00, and a low estimate of $11.50. Surpassing the previous average price target of $12.62, the current average has increased by 2.06%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741039222_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Teladoc Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Teladoc Health: A Closer Look</h2>
<p>Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.</p>
<h3>A Deep Dive into Teladoc Health's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Teladoc Health's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-3.03%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-7.56%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-3.23%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-1.37%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Teladoc Health's debt-to-equity ratio is below the industry average at <strong>1.06</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Where Teladoc Health Stands With Analysts

<p>Goldman Sachs  analyst David Roman   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $16 to $13.</p>


Price Target

Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $13

<p>Needham  analyst Ryan MacDonald   reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.</p>


Reiteration

Needham Reiterates Hold on Teladoc Healthto Hold

<p>Piper Sandler  analyst Jessica Tassan   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Overweight and lowers the price target from $13 to $12.</p>


Piper Sandler Maintains Overweight on Teladoc Health, Lowers Price Target to $12

WIIM

Teladoc shares are trading lower following soft Q1 revenue guidance.

Teladoc Sees FY25 Revenue $2.468B-$2.576B vs $2.543B Est., Sees Q1 Revenue $608M-$629M vs $632.911M Est.

<p>Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 64.71 percent decrease over losses of $(0.17) per share from the same period last year.  The company reported quarterly sales of $640.500 million which beat the analyst consensus estimate of $639.552 million by 0.15 percent.  This is a 3.03 percent decrease over sales of $660.527 million the same period last year.</p>


Earnings Beats

Earnings Misses

Teladoc Health Q4 2024 GAAP EPS $(0.28) Misses $(0.23) Estimate, Sales $640.500M Beat $639.552M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

<p><a href="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/" title="https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/">https://www.blueorcacapital.com/blue-orca-is-short-teladoc-health-inc/</a></p>


Short Sellers

Watching Teladoc Health; 'Blue Orca Capital Is Short Teledoc Health' Issues Report On The Company

<p>Goldman Sachs  analyst David Roman   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and raises the price target from $14 to $16.</p>


Goldman Sachs Maintains Buy on Teladoc Health, Raises Price Target to $16

<p>6 analysts have shared their evaluations of Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.67, a high estimate of $14.00, and a low estimate of $11.50. This upward trend is evident, with the current average reflecting a 9.22% increase from the previous average price target of $11.60.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739368852_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$14.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teladoc Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Teladoc Health analyst ratings.</strong></a></p>
<h2>Discovering Teladoc Health: A Closer Look</h2>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<h3>Teladoc Health: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Teladoc Health's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately <strong>-2.99%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Teladoc Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-5.2%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Teladoc Health's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-2.21%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Teladoc Health's ROA excels beyond industry benchmarks, reaching <strong>-0.94%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Teladoc Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.05</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing Teladoc Health: Insights From 6 Financial Analysts

<p>B of A Securities  analyst Allen Lutz   maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and raises the price target from $11.5 to $13.5.</p>


B of A Securities Maintains Neutral on Teladoc Health, Raises Price Target to $13.5

<p>Deep-pocketed investors have adopted a bullish approach towards Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TDOC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Teladoc Health. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 50% leaning bullish and 33% bearish. Among these notable options, 2 are puts, totaling $100,220, and 10 are calls, amounting to $394,909.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $17.5 for Teladoc Health over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Teladoc Health options trades today is 1654.0 with a total volume of 13,969.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Teladoc Health's big money trades within a strike price range of $7.5 to $17.5 over the last 30 days.</p>
<h3>Teladoc Health Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1739220323_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.55</td>
<td>$4.45</td>
<td>$4.5</td>
<td>$10.00</td>
<td>$90.0K</td>
<td>3.6K</td>
<td>237</td>
</tr>
<tr>
<td>TDOC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.85</td>
<td>$1.6</td>
<td>$1.85</td>
<td>$12.50</td>
<td>$74.0K</td>
<td>175</td>
<td>407</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$0.9</td>
<td>$0.82</td>
<td>$0.88</td>
<td>$14.00</td>
<td>$57.0K</td>
<td>3.7K</td>
<td>2.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.92</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$17.50</td>
<td>$41.0K</td>
<td>2.2K</td>
<td>912</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.15</td>
<td>$6.8</td>
<td>$6.89</td>
<td>$10.00</td>
<td>$34.4K</td>
<td>538</td>
<td>93</td>
</tr>
</tbody>
</table>
</p>
<h3>About Teladoc Health</h3>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<p>Following our analysis of the options activities associated with Teladoc Health, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Teladoc Health</h3>
<ul>
<li>With a trading volume of 14,344,358, the price of TDOC is up by 7.14%, reaching $13.88.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 16 days from now.</li>
</ul>
<h3>Expert Opinions on Teladoc Health</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $11.833333333333334.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Teladoc Health, which currently sits at a price target of $11.<br />
&#x2A; An analyst from RBC Capital persists with their Outperform rating on Teladoc Health, maintaining a target price of $12.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Teladoc Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Unpacking the Latest Options Trading Trends in Teladoc Health

<p>These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?</p>
<ol>
<li><strong>Kingsoft Cloud</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) stock upped 34.77%.</li>
<li><strong>Oklo Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock jumped 33.36%. Board member Chris Wright was confirmed as the U.S. Secretary of Energy on February 3, 2025. As a result, he has <a href="https://www.benzinga.com//node/43525625" target="_blank" rel="noreferrer noopener">stepped down from Oklo's Board</a>.</li>
<li><strong>AST SpaceMobile, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares escalated 30.98% after <strong>Cantor Fitzgerald</strong> analyst Colin Canfield initiated coverage with an Overweight rating <a href="https://www.benzinga.com/quote/ASTS/analyst-ratings" target="_blank" rel="noreferrer noopener">and price forecast of&nbsp;$30</a>.</li>
<li><strong>VNET Group, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) shares surged 29.12%.</li>
<li><strong>Teladoc Health, Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) shares rose 27.46% after the company announced it would acquire <strong>Catapult Health</strong> in an all-<a href="https://www.benzinga.com//node/43490439" target="_blank" rel="noreferrer noopener">cash $65 million transaction</a>.</li>
<li><strong>GDS Holdings Limited </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) shares were up 25.68%.&nbsp;China recently raised tariffs on certain U.S. imports, and reports suggested that the U.S. is exploring adding Shein and Temu to the ‘forced labor' list.</li>
<li><strong>Magnite, Inc.'s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) stock gained 23.08% last week following a report indicating <a href="https://www.businessinsider.com/elon-musk-x-signs-programmatic-ad-partnership-magnite-2025-2" target="_blank" rel="noreferrer noopener">it signed a partnership</a> with Elon Musk's X, formerly Twitter.</li>
<li><strong>SolarWinds Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) stock grew 23.05% after the company announced that <strong>Turn/River Capital</strong> would acquire it <a href="https://www.benzinga.com//node/43559292" target="_blank" rel="noreferrer noopener">for &nbsp;$4.4 billion</a>.</li>
<li><strong>Lions Gate Entertainment Corp</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) stock upped 22.68% last week after the company reported better-than-expected Q3 earnings.</li>
<li><strong>IREN Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) shares rose 22.02% last week <a href="https://www.benzinga.com//node/43524343" target="_blank" rel="noreferrer noopener">after reporting it mined</a> 525 Bitcoins (CRYPTO: BTC/USD) in January.</li>
</ol>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><em><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></em></strong></li>
<li><strong><em><a href="https://www.benzinga.com/news/large-cap/25/02/43580887/estee-lauder-moderna-and-paypal-are-among-top-10-large-cap-losers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></em></strong></li>
</ul>
<p><em>Photo via ASTS</em></p>


AST SpaceMobile, Teladoc Health And IREN Are Among Top 10 Mid Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

Teladoc shares are trading higher on continued strength amid bullish comments Citron Research.

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Teladoc Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TDOC, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Teladoc Health.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $80,790, and 7 are calls, for a total amount of $305,754.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.5 to $35.0 for Teladoc Health over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Teladoc Health's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Teladoc Health's whale activity within a strike price range from $7.5 to $35.0 in the last 30 days. </p>
<h3>Teladoc Health 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1738942237_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.83</td>
<td>$2.8</td>
<td>$2.83</td>
<td>$15.00</td>
<td>$86.5K</td>
<td>4.0K</td>
<td>1.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$3.35</td>
<td>$3.1</td>
<td>$3.35</td>
<td>$12.50</td>
<td>$46.7K</td>
<td>486</td>
<td>140</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$15.00</td>
<td>$45.5K</td>
<td>3.2K</td>
<td>1.4K</td>
</tr>
<tr>
<td>TDOC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$5.95</td>
<td>$5.85</td>
<td>$5.85</td>
<td>$17.50</td>
<td>$43.2K</td>
<td>0</td>
<td>75</td>
</tr>
<tr>
<td>TDOC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$1.52</td>
<td>$1.32</td>
<td>$1.5</td>
<td>$12.50</td>
<td>$37.5K</td>
<td>3.7K</td>
<td>465</td>
</tr>
</tbody>
</table>
</p>
<h3>About Teladoc Health</h3>
<p>Teladoc Health is a virtual health provider with a telehealth platform delivering on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has partnered with employers, health plans, and health systems to offer network access to their members; it has also started to market directly to consumers while expanding its service portfolio.</p>
<p>Having examined the options trading patterns of Teladoc Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Teladoc Health</h3>
<ul>
<li>With a trading volume of 4,468,528, the price of TDOC is up by 3.43%, reaching $12.38.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>What The Experts Say On Teladoc Health</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $11.833333333333334.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Teladoc Health, targeting a price of $12.<br />
&#x2A; An analyst from B of A Securities persists with their Neutral rating on Teladoc Health, maintaining a target price of $11.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Teladoc Health, maintaining a target price of $12. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Teladoc Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Check Out What Whales Are Doing With TDOC

<p><a href="https://x.com/CitronResearch/status/1887875209966805075" title="https://x.com/CitronResearch/status/1887875209966805075">https://x.com/CitronResearch/status/1887875209966805075</a></p>


DOCS

Citron Research Posts On X "$TDOC got solid feedback on yesterday's post. Look at $DOCS today—digital tools fueling the telemedicine boom. Read their report:..."

Teladoc Health shares are trading higher amid a post from CitronResearch on X stating the company is "quietly turning into a cash-generating machine". Also, B of A Securities raised its price target on the stock from $10.5 to $11.5.

CitronResearch Tweeted $TDOC – The Under-the-Radar AI Play Teladoc just acquired Catapult Health, doubling down on preventive care + virtual health. The market still treats it like a pandemic relic, but it's quietly turning into a cash-generating machine. While AI hype stocks trade at wild multiples

Small Cap

Opinion

Press Releases

Healthcare AI Adoption Accelerates as Industry Eyes $125 Billion Growth by 2028

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

Teladoc Health to Announce Fourth Quarter 2024 Financial Results

Teladoc Health to Acquire Catapult Health, Advancing Integrated Care Strategy

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Legal

TDOC INVESTIGATION: Teladoc Health, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Teladoc Health Inc. (NYSE: TDOC) and Urges Investors with Substantial Losses to Contact the Firm

Teladoc Health to Participate in Upcoming Investor Conference

Teladoc Health Reports Full Year and Fourth Quarter 2024 Results

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teladoc Health, Inc. - TDOC

Comments

Teladoc Health

매도 수량

Teladoc Health (NYSE:TDOC) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌